文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19患者金黄色葡萄球菌呼吸机相关性肺炎的临床特征及与肺部菌群失调的潜在关系

Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis.
PubMed 文献 · Crit Care · 2021-06-07
一句话结论COVID-19合并SA-VAP患者晚发型、MRSA及菌血症比例更高,但ICU死亡率无显著差异;SAPS II和初始不恰当抗菌治疗与ICU死亡独立相关。

该前瞻性研究在意大利罗马Fondazione Policlinico Universitario A. Gemelli IRCCS的两个内科ICU纳入2020年3月20日至10月30日期间发生SA-VAP的COVID-19患者40例,按SAPS II和SOFA评分1:2匹配非COVID-19 SA-VAP患者80例。COVID-19组晚发型(87.5% vs 63.8%,p=0.01)、耐甲氧西林(65.0% vs 27.5%,p<0.01)及菌血症(47.5% vs 6.3%,p<0.01)比例更高;两组ICU死亡率(p=0.12)、临床治愈(p=0.20)和微生物清除(p=0.31)无显著差异。多因素logistic回归显示SAPS II和初始不恰当抗菌治疗与ICU死亡独立相关。肺部菌群分析(COVID-19 10例 vs 非COVID-19 16例)显示两组整体群落组成显著不同(非加权UniFrac距离,R2 0.15349;p<0.01),COVID-19组物种多样性更低(94.4 ± 44.9 vs 152.5 ± 41.8;p<0.01),金黄色葡萄球菌(log2倍数变化29.5)、咽峡炎链球菌咽峡亚种(log2倍数变化24.9)和Olsenella(log2倍数变化25.7)显著富集。

要点

  • COVID-19合并SA-VAP患者晚发型比例87.5% vs 非COVID-19 63.8%(p=0.01),耐甲氧西林比例65.0% vs 27.5%(p<0.01),菌血症比例47.5% vs 6.3%(p<0.01)。
  • 两组ICU死亡率(p=0.12)、临床治愈(p=0.20)、微生物清除(p=0.31)无显著差异。
  • 多因素logistic回归显示SAPS II和初始不恰当抗菌治疗与ICU死亡独立相关。
  • 肺部菌群整体组成两组显著不同(非加权UniFrac距离,R2 0.15349;p<0.01),COVID-19组物种多样性更低(94.4 ± 44.9 vs 152.5 ± 41.8;p<0.01)。
  • COVID-19组金黄色葡萄球菌(log2倍数变化29.5)、咽峡炎链球菌咽峡亚种(log2倍数变化24.9)和Olsenella(log2倍数变化25.7)显著富集。

适用人群与场景

  • 意大利罗马Fondazione Policlinico Universitario A. Gemelli IRCCS两个内科ICU收治的、2020年3月20日至2020年10月30日期间发生SA-VAP的住院COVID-19患者(病例组,40例)。
  • 按SAPS II和SOFA评分1:2匹配的非COVID-19 SA-VAP患者(对照组,80例)。
  • 肺部菌群分析亚组:COVID-19患者10例和非COVID-19患者16例。

研究设计与关键结果

  • 前瞻性研究,纳入COVID-19 SA-VAP患者40例,按SAPS II和SOFA评分1:2匹配非COVID-19 SA-VAP患者80例,比较临床、微生物学及肺部菌群数据。
  • COVID-19组晚发型SA-VAP比例87.5% vs 非COVID-19组63.8%(p=0.01),耐甲氧西林比例65.0% vs 27.5%(p<0.01),菌血症比例47.5% vs 6.3%(p<0.01)。
  • 两组ICU死亡率(p=0.12)、临床治愈(p=0.20)和微生物清除(p=0.31)无统计学显著差异。
  • 多因素logistic回归分析显示SAPS II和初始不恰当抗菌治疗与ICU死亡独立相关。
  • 肺部菌群分析(COVID-19 10例 vs 非COVID-19 16例)显示整体微生物群落组成显著不同(非加权UniFrac距离,R2 0.15349;p<0.01)。
  • COVID-19组物种多样性低于非COVID-19组(94.4 ± 44.9 vs 152.5 ± 41.8;p<0.01)。
  • COVID-19组金黄色葡萄球菌(log2倍数变化29.5)、咽峡炎链球菌咽峡亚种(log2倍数变化24.9)和Olsenella(log2倍数变化25.7)显著富集。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU收治的COVID-19机械通气患者中,发生SA-VAP时晚发型、耐甲氧西林及菌血症比例更高,SAPS II和初始不恰当抗菌治疗与ICU死亡独立相关;作者认为COVID-19似乎显著影响SA-VAP的微生物学和临床特征,并与特殊的肺部菌群组成相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hospitalized patients with COVID-19 admitted to the intensive care unit (ICU) and requiring mechanical ventilation are at risk of ventilator-associated bacterial infections secondary to SARS-CoV-2 infection. Our study aimed to investigate clinical features of Staphylococcus aureus ventilator-associated pneumonia (SA-VAP) and, if bronchoalveolar lavage samples were available, lung bacterial community features in ICU patients with or without COVID-19.

METHODS: We prospectively included hospitalized patients with COVID-19 across two medical ICUs of the Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy), who developed SA-VAP between 20 March 2020 and 30 October 2020 (thereafter referred to as cases). After 1:2 matching based on the simplified acute physiology score II (SAPS II) and the sequential organ failure assessment (SOFA) score, cases were compared with SA-VAP patients without COVID-19 (controls). Clinical, microbiological, and lung microbiota data were analyzed.

RESULTS: We studied two groups of patients (40 COVID-19 and 80 non-COVID-19). COVID-19 patients had a higher rate of late-onset (87.5% versus 63.8%; p = 0.01), methicillin-resistant (65.0% vs 27.5%; p < 0.01) or bacteremic (47.5% vs 6.3%; p < 0.01) infections compared with non-COVID-19 patients. No statistically significant differences between the patient groups were observed in ICU mortality (p = 0.12), clinical cure (p = 0.20) and microbiological eradication (p = 0.31). On multivariable logistic regression analysis, SAPS II and initial inappropriate antimicrobial therapy were independently associated with ICU mortality. Then, lung microbiota characterization in 10 COVID-19 and 16 non-COVID-19 patients revealed that the overall microbial community composition was significantly different between the patient groups (unweighted UniFrac distance, R2 0.15349; p < 0.01). Species diversity was lower in COVID-19 than in non COVID-19 patients (94.4 ± 44.9 vs 152.5 ± 41.8; p < 0.01). Interestingly, we found that S. aureus (log2 fold change, 29.5), Streptococcus anginosus subspecies anginosus (log2 fold change, 24.9), and Olsenella (log2 fold change, 25.7) were significantly enriched in the COVID-19 group compared to the non-COVID-19 group of SA-VAP patients.

CONCLUSIONS: In our study population, COVID-19 seemed to significantly affect microbiological and clinical features of SA-VAP as well as to be associated with a peculiar lung microbiota composition.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. De Pascale G, De Maio F, Carelli S, et al. Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis. Crit Care. 2021. PMID: 34099016. doi:10.1186/s13054-021-03623-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。